Nuveen
AVIR icon

Nuveen’s Atea Pharmaceuticals AVIR Stock Holding History

Nuveen’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
284,283
+41,180
+17% +$205K ﹤0.01% 2800
2026
Q1 		$1.31M Buy
243,103
+2,515
+1% +$11.6K ﹤0.01% 2461
2025
Q4 		$859K Sell
240,588
-15,259
-6% -$48.5K ﹤0.01% 2682
2025
Q3 		$742K Hold
255,847
– – ﹤0.01% 2756
2025
Q2 		$921K Sell
255,847
-35,244
-12% -$105K ﹤0.01% 2646
2025
Q1 		$870K Hold
291,091
– – ﹤0.01% 2700
2024
Q4 		$975K Hold
291,091
– – ﹤0.01% 2723
2024
Q3 		$975K Hold
291,091
– – ﹤0.01% 2773
2024
Q2 		$964K Hold
291,091
– – ﹤0.01% 2746
2024
Q1 		$1.18M Hold
291,091
– – ﹤0.01% 2632
2023
Q4 		$888K Buy
291,091
+1,598
+0.6% +$4.84K ﹤0.01% 2788
2023
Q3 		$868K Sell
289,493
-2,598
-0.9% -$8.84K ﹤0.01% 2631
2023
Q2 		$1.09M Sell
292,091
-93,331
-24% -$349K ﹤0.01% 2619
2023
Q1 		$1.29M Buy
385,422
+72,018
+23% +$292K ﹤0.01% 2511
2022
Q4 		$1.51M Sell
313,404
-34,519
-10% -$175K ﹤0.01% 2502
2022
Q3 		$1.98M Buy
347,923
+77,760
+29% +$595K ﹤0.01% 2409
2022
Q2 		$1.92M Buy
270,163
+17,150
+7% +$117K ﹤0.01% 2453
2022
Q1 		$1.75M Sell
253,013
-15,085
-6% -$102K ﹤0.01% 2563
2021
Q4 		$2.4M Sell
268,098
-592
-0.2% -$9.22K ﹤0.01% 2481
2021
Q3 		$9.42M Sell
268,690
-33,550
-11% -$931K ﹤0.01% 1822
2021
Q2 		$6.49M Buy
302,240
+247,027
+447% +$7.42M ﹤0.01% 2107
2021
Q1 		$3.41M Buy
55,213
+2,122
+4% +$143K ﹤0.01% 2356
2020
Q4 		$2.22M Buy
+53,091
New +$1.71M ﹤0.01% 2458

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen's AVIR Position: Q2 2026 in Review

Nuveen increased its Atea Pharmaceuticals (AVIR) stake by 17% in Q2 2026, buying an estimated $205K and bringing the position to 284,283 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2800.

Nuveen first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $9.42M in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Nuveen held 284,283 shares of Atea Pharmaceuticals worth $1.32M as of Q2 2026.
  • Nuveen bought 41,180 Atea Pharmaceuticals shares in Q2 2026, an estimated $205K.
  • Atea Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2800 holding.
  • Nuveen first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Nuveen's Atea Pharmaceuticals position peaked at $9.42M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.